Trial
NCT05094206
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
Phase ITERMINATEDREGULATORYConfidence: MEDIUM
Sponsor
Medical College of Wisconsin
Collaborators
Miltenyi Biotec, Inc.
Condition
B-cell Non Hodgkin Lymphoma
Intervention
0.75x10^6 cells/kg CAR20.19.22 cells
Why stopped
Treated four patients: 2 at a dose of 1x10\^6 cells/kg and 2 ad at dose of 2.5x10\^6 cells/kg. All four patients had no in-vivo expansion and no meaningful response to therapy. At this point per FDA guidance we will not be treating more patients.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-19